Orchid Pharma Ltd

AI
Orchid Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents
AI

Orchid Pharma Ltd

₹ 1,002 2.24%
21 Aug - close price
orchidpharma.com BSE: 524372 NSE: ORCHPHARMA
About

Orchid Pharma is a pharmaceutical company engaged in the development and manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms. It is also engaged in research of new drugs. [1]

Key Points

Product Segments FY24
The company operates mainly in the Cephalosporins-based active pharmaceutical ingredients (API) business. These APIs are primarily used in anti-bacterial, anti-biotic, and anti-inflammatory formulations. [1][2]

Website BSE NSE
  • Market Cap ₹ 6,001 Cr.
  • Current Price ₹ 1,002
  • High / Low ₹ 1,133 / 471
  • Stock P/E 124
  • Book Value ₹ 270
  • Dividend Yield 0.00 %
  • ROCE 3.33 %
  • ROE 3.11 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has delivered good profit growth of 18.7% CAGR over last 5 years

Cons

  • Stock is trading at 3.71 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Tax rate seems low
  • Company has a low return on equity of 6.78% over last 3 years.
  • Earnings include an other income of Rs.42.5 Cr.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 1000 BSE Healthcare

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
183 199 221 217 244 223 217 237 263 194 207 368 304
161 175 185 188 211 193 191 203 269 194 204 336 289
Operating Profit 22 24 36 29 33 30 26 34 -6 -1 3 32 15
OPM % 12% 12% 16% 13% 14% 13% 12% 14% -2.1% -0.3% 1.4% 9% 4.9%
2 8 7 13 8 8 10 6 16 15 3 14 10
Interest 6 4 4 3 3 3 4 4 2 4 3 2 2
Depreciation 8 8 9 8 8 9 9 9 11 9 9 11 11
Profit before tax 11 20 31 30 29 26 24 28 -2 2 -6 33 12
Tax % 0% 0% 0% -11% 0% 0% 0% 0% 0% 0% 0% 0% 0%
11 20 31 33 29 26 24 28 -2 2 -6 33 12
EPS in Rs 2.13 3.99 6.02 6.54 5.74 5.05 4.71 5.49 -0.48 0.44 -1.15 6.44 2.35
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 18m Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
1,736 879 755 644 584 481 451 557 666 819 922 1,233 1,073
1,416 705 740 622 590 470 392 498 581 708 798 1,195 1,024
Operating Profit 320 174 15 22 -6 11 59 59 84 111 124 38 49
OPM % 18% 20% 2.0% 3.5% -1.1% 2.4% 13% 11% 13% 14% 13% 3.1% 4.6%
156 -28 -59 20 42 -37 -15 57 57 30 32 49 42
Interest 537 294 347 310 7 6 52 33 33 17 15 9 11
Depreciation 321 143 146 133 130 118 109 87 55 33 34 43 40
Profit before tax -383 -292 -537 -401 -101 -150 -117 -5 54 92 106 35 41
Tax % -50% -6% -9% -12% 0% 0% 0% 0% 0% -4% 0% 0%
-191 -274 -489 -355 -101 -150 -117 -5 54 95 106 35 41
EPS in Rs -22.41 -30.83 -54.91 -39.94 -11.36 -36.71 -28.70 -1.18 13.28 18.68 20.99 6.83 8.08
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: 3%
5 Years: 22%
3 Years: 23%
TTM: 14%
Compounded Profit Growth
10 Years: 8%
5 Years: 19%
3 Years: 44%
TTM: -36%
Stock Price CAGR
10 Years: 39%
5 Years: 19%
3 Years: 21%
1 Year: 30%
Return on Equity
10 Years: %
5 Years: 5%
3 Years: 7%
Last Year: 3%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 85 89 89 89 89 41 41 41 41 51 51 51
Reserves 354 82 -432 -763 -844 757 641 637 691 1,168 1,273 1,319
3,211 3,214 3,106 3,202 3,230 566 453 268 331 135 175 185
506 577 595 683 518 86 90 148 160 199 198 195
Total Liabilities 4,156 3,963 3,358 3,211 2,993 1,450 1,224 1,094 1,223 1,552 1,697 1,750
1,697 1,540 1,402 1,291 1,161 858 670 584 573 616 613 670
CWIP 282 280 288 272 278 26 7 10 46 24 44 95
Investments 125 125 125 125 0 0 15 49 50 69 69 256
2,053 2,017 1,543 1,523 1,553 566 531 452 554 842 970 729
Total Assets 4,156 3,963 3,358 3,211 2,993 1,450 1,224 1,094 1,223 1,552 1,697 1,750

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
-370 211 402 6 15 80 24 90 13 131 27 119
1,334 -1 -176 -28 45 167 67 113 -27 -316 -37 -125
-597 -287 -465 33 -0 -250 -165 -217 31 167 25 -8
Net Cash Flow 367 -76 -239 11 60 -3 -73 -14 18 -18 16 -15
Free Cash Flow -452 210 393 -0 9 76 24 235 -13 76 -41 -38
CFO/OP -101% 121% 2,669% 57% -308% 615% 33% 156% 16% 117% 23% 307%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 61 156 101 82 88 50 107 105 116 84 96 78
Inventory Days 113 183 196 204 219 257 240 201 217 199 219 111
Days Payable 138 307 410 361 354 110 109 140 130 135 114 69
Cash Conversion Cycle 36 32 -113 -74 -47 197 237 165 204 148 200 120
Working Capital Days -32 -127 -504 -901 -1,159 197 330 121 79 140 152 115
ROCE % 1% 2% -3% -3% -5% -4% -4% -2% 5% 9% 9% 3%

Insights

In beta
Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Exports as % of Total Revenue (FOB / Turnover)
%

Log in to view insights

Please log in to see hidden values.

Login
R&D Spend as % of Total Turnover
%
Permanent Employees on Rolls
count
Cumulative US ANDA Approvals
count
Cumulative US DMF Filings
count
Oral API Sales Volume
MT
Sterile API Sales Volume
MT
Regulated Markets Share of Revenue
%
R&D Expenditure (Percentage of Turnover)
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
72.40% 69.84% 69.84% 69.84% 69.84% 69.84% 69.84% 69.84% 69.84% 69.84% 69.84% 69.84%
8.08% 4.14% 1.96% 1.42% 1.94% 2.53% 2.69% 1.39% 1.56% 1.17% 0.87% 0.80%
12.46% 14.51% 17.73% 18.93% 18.30% 19.00% 20.10% 19.43% 19.04% 19.38% 20.24% 20.75%
7.05% 11.52% 10.47% 9.82% 9.94% 8.63% 7.37% 9.34% 9.57% 9.61% 9.04% 8.62%
No. of Shareholders 29,19736,93136,72034,69536,36334,15834,30339,82738,15535,70935,11833,433

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls